APGE -
Apogee Therapeutics, Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
53.95 1.83 (3.39%) |
--- |
--- |
--- |
-0.15 (-0.27%) |
2.59 (4.87%) |
--- |
-0.15 (-0.27%) |
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Market Period:
AfterHours
Earnings & Ratios
- Basic EPS:
- -1.13
- Diluted EPS:
- -1.13
- Basic P/E:
- -49.3628
- Diluted P/E:
- -49.3628
- RSI(14) 1m:
- 69.49
- VWAP:
- 55.96
- RVol:
- 1.0596
Events
Period |
Kind |
Movement |
Occurred At |
Related News
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
Oct 10, 2025 20:01
Why Apogee Therapeutics Stock Triumphed on Thursday
Oct 09, 2025 21:26
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
Oct 09, 2025 01:52
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
Jul 07, 2025 10:00
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Jul 06, 2025 22:00
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
May 12, 2025 10:00
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
May 01, 2025 12:00
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Mar 03, 2025 11:00
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Feb 03, 2025 12:00
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Dec 02, 2024 11:00